Jaume Capdevila
Impact in
- Epidemiology top 0.1%
- Neuroendocrine Tumor Research Advances
- Oncology top 0.5%
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
- Epidemiology 134
- Neuroendocrine Tumor Research Advances 134
- Oncology 79
- Colorectal Cancer Treatments and Studies 33
- Colorectal Cancer Surgical Treatments 24
- Cancer Immunotherapy and Biomarkers 8
- Co-authors
- Marianne Ellen Pavel (14 shared papers)Edward M. Wolin (11 shared papers)Kjell Öberg (3 shared papers)Guido Rindi (10 shared papers)Martyn Evan Caplin (11 shared papers)Catherine Lombard‐Bohas (10 shared papers)James C. Yao (7 shared papers)Eric Van Cutsem (10 shared papers)
- Journals
- Annals of Oncology (71 papers)European Journal of Cancer (16 papers)Clinical & Translational Oncology (13 papers)Neuroendocrinology (12 papers)The Oncologist (9 papers)
- Partner nations
- SpainUnited StatesItaly
In The Last Decade
Jaume Capdevila
288 papers receiving 15k citations
Jaume Capdevila's Hit Papers
Peers
Comparison fields: 5 of 114
- Epidemiology 8.1k
- Oncology 3.3k
- Endocrinology, Diabetes and Metabolism 1.5k
- Cancer Research 443
- Radiology, Nuclear Medicine and Imaging 513
Countries citing papers authored by Jaume Capdevila
This map shows the geographic impact of Jaume Capdevila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Capdevila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Capdevila more than expected).
Fields of papers citing papers by Jaume Capdevila
This network shows the impact of papers produced by Jaume Capdevila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Capdevila. The network helps show where Jaume Capdevila may publish in the future.
Co-authors
The 25 scholars most cited alongside Jaume Capdevila, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 305 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Everolimus for Advanced Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 2355 |
| 2 | Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors Hit paper breakdown → | 2014 | 1485 |
| 3 | Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2020 | 1124 |
| 4 | ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2016 | 1027 |
| 5 | ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site Hit paper breakdown → | 2016 | 816 |
| 6 | Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids Hit paper breakdown → | 2015 | 521 |
| 7 | 2010 | 352 | |
| 8 | 2012 | 319 | |
| 9 | 2020 | 264 | |
| 10 | 2017 | 223 | |
| 11 | Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery Hit paper breakdown → | 2023 | 221 |
| 12 | 2016 | 218 | |
| 13 | [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study Hit paper breakdown → | 2024 | 214 |
| 14 | Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2021 | 191 |
| 15 | 2016 | 190 | |
| 16 | Consensus on molecular imaging and theranostics in neuroendocrine neoplasms Hit paper breakdown → | 2021 | 173 |
| 17 | 2020 | 153 | |
| 18 | 2020 | 129 | |
| 19 | 2015 | 126 | |
| 20 | Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer Hit paper breakdown → | 2023 | 123 |
About Jaume Capdevila
Jaume Capdevila is a scholar working on Epidemiology, Oncology, Endocrinology, Diabetes and Metabolism, Cancer Research and Surgery, having authored 305 papers that have together received 15.2k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (134 papers), Thyroid Cancer Diagnosis and Treatment (61 papers), Colorectal Cancer Treatments and Studies (33 papers), Colorectal Cancer Surgical Treatments (24 papers), Cancer Immunotherapy and Biomarkers (8 papers), Cancer Genomics and Diagnostics (7 papers), Adrenal and Paraganglionic Tumors (6 papers) and Epigenetics and DNA Methylation (6 papers). The work is most often cited by research in Epidemiology (8.1k citations), Oncology (3.3k citations), Endocrinology, Diabetes and Metabolism (1.5k citations), Cancer Research (443 citations) and Radiology, Nuclear Medicine and Imaging (513 citations). Jaume Capdevila has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Marianne Ellen Pavel, Edward M. Wolin, Kjell Öberg, Guido Rindi, Martyn Evan Caplin, Catherine Lombard‐Bohas, James C. Yao, Eric Van Cutsem, Réza Kianmanesh and Timothy J. Hobday. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Clinical & Translational Oncology, Neuroendocrinology and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.